Jeff Chiprin
Known title: Chief Commercial OfficerCIK: 0002047489
Associated companies
Transaction History
| IRMD | ▲ Buy | Option Exercise | 996 | — | 12/11/2025 | View on chart |
| IRMD | ▼ Sell | Tax Withholding | 309 | $30K | 12/11/2025 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 996 | — | 12/11/2025 | View on chart |
| IRMD | ▼ Sell | Tax Withholding | 309 | $30K | 12/11/2025 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
iRadimed Gets Needham Hold Rating and Conference Participation
Needham initiated coverage on iRadimed with a Hold rating, while the company announced it will speak at the ROTH Healthcare Opportunities Conference. These developments add analyst visibility to the stock, which is currently trading near its 52-week high. The new coverage provides a fresh perspective on the company's position in the medical imaging sector.
iRadimed Gets Needham Hold Rating and Conference Participation. Needham initiated coverage on iRadimed with a Hold rating, while the company announced it will speak at the ROTH Healthcare Opportunities Conference. These developments add analyst visibility to the stock, which is currently trading near its 52-week high. The new coverage provides a fresh perspective on the company's position in the medical imaging sector.